Abstract
Telomeres are the protective end caps of eukaryotic chromosomes and they determine the proliferative lifespan of somatic cells, as the protectors of cell replication. Telomere length in leucocytes reflects telomere length in other somatic cells. Leucocyte telomere length can be a biomarker of human ageing. The risk of diseases associated with reduced cell proliferation and tissue degeneration, including aging or aging-associated diseases, such as dyskeratosis congenita, cardiovascular diseases, pulmonary fibrosis and aplastic anemia, is correlated with an increase in the shortening of telomeres. On the other hand, the risk of diseases that are associated with increased proliferative growth, including major cancers, is correlated with long telomeres. In most of the cancers, a telomere maintenance mechanism during DNA replication is essential. The reactivation of the functional ribonucleoprotein holoenzyme complex (telomerase) starts the cascade from normal and premalignant somatic cells to advanced malignant cells. Telomerase is overexpressed during the development of cancer and embryonic stem cells, through controlling genome integrity, cancer formation and stemness. Cancer cells have mechanisms to maintain telomeres to avoid initiation of cellular senescence or apoptosis, and halting cell division by critically short telomeres. Modulation of the human telomerase reverse transcriptase is the rate-limiting step for the production of functional telomerase and telomere maintenance. The human telomerase reverse transcriptase promoter promotes its gene expression only in tumor cells, but not in normal cells. Some cancers activate an alternative expansion of telomeres maintenance mechanism via DNA recombination to reduce the shortening of their telomeres. Not only heritability but also oxidative stress, inflammation, environmental factors, and therapeutic interventions have an effect on telomere shortening, explaining the variability in telomere length across individuals. There have been a large number of publications, which correlate human diseases with progressive telomere shortening. Telomere length of an individual at birth is also important to follow up telomere shortening, and it can be used as a biomarker for healthy aging. On the other hand, understanding of cellular stress factors, which affect stem cell behavior, will be useful in regeneration or treatment of cancer and age-associated diseases. In this review, we will understand the connection between stem cell and telomere biology, cancer, and aging-associated diseases. This connection may be useful for discovering novel drug targets and improve outcomes for patients having cancer and aging-associated diseases.
Keywords: Stem cells, telomere, telomerase, DNA repair, aging, cancer.
Current Stem Cell Research & Therapy
Title:Regulation and Effect of Telomerase and Telomeric Length in Stem Cells
Volume: 16 Issue: 7
Author(s): Basak Celtikci, Gulnihal Kulaksiz Erkmen and Zeliha Gunnur Dikmen*
Affiliation:
- Department of Medical Biochemistry, Faculty of Medicine, Hacettepe University, Sihhiye 06100, Ankara,Turkey
Keywords: Stem cells, telomere, telomerase, DNA repair, aging, cancer.
Abstract: Telomeres are the protective end caps of eukaryotic chromosomes and they determine the proliferative lifespan of somatic cells, as the protectors of cell replication. Telomere length in leucocytes reflects telomere length in other somatic cells. Leucocyte telomere length can be a biomarker of human ageing. The risk of diseases associated with reduced cell proliferation and tissue degeneration, including aging or aging-associated diseases, such as dyskeratosis congenita, cardiovascular diseases, pulmonary fibrosis and aplastic anemia, is correlated with an increase in the shortening of telomeres. On the other hand, the risk of diseases that are associated with increased proliferative growth, including major cancers, is correlated with long telomeres. In most of the cancers, a telomere maintenance mechanism during DNA replication is essential. The reactivation of the functional ribonucleoprotein holoenzyme complex (telomerase) starts the cascade from normal and premalignant somatic cells to advanced malignant cells. Telomerase is overexpressed during the development of cancer and embryonic stem cells, through controlling genome integrity, cancer formation and stemness. Cancer cells have mechanisms to maintain telomeres to avoid initiation of cellular senescence or apoptosis, and halting cell division by critically short telomeres. Modulation of the human telomerase reverse transcriptase is the rate-limiting step for the production of functional telomerase and telomere maintenance. The human telomerase reverse transcriptase promoter promotes its gene expression only in tumor cells, but not in normal cells. Some cancers activate an alternative expansion of telomeres maintenance mechanism via DNA recombination to reduce the shortening of their telomeres. Not only heritability but also oxidative stress, inflammation, environmental factors, and therapeutic interventions have an effect on telomere shortening, explaining the variability in telomere length across individuals. There have been a large number of publications, which correlate human diseases with progressive telomere shortening. Telomere length of an individual at birth is also important to follow up telomere shortening, and it can be used as a biomarker for healthy aging. On the other hand, understanding of cellular stress factors, which affect stem cell behavior, will be useful in regeneration or treatment of cancer and age-associated diseases. In this review, we will understand the connection between stem cell and telomere biology, cancer, and aging-associated diseases. This connection may be useful for discovering novel drug targets and improve outcomes for patients having cancer and aging-associated diseases.
Export Options
About this article
Cite this article as:
Celtikci Basak , Erkmen Kulaksiz Gulnihal and Dikmen Gunnur Zeliha *, Regulation and Effect of Telomerase and Telomeric Length in Stem Cells, Current Stem Cell Research & Therapy 2021; 16 (7) . https://dx.doi.org/10.2174/1574888X15666200422104423
DOI https://dx.doi.org/10.2174/1574888X15666200422104423 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Oxidative Stress in Anti-tumor Necrosis Factor Antibody Treatment in Crohn´s Disease
Current Medicinal Chemistry Osteoblast-n-Osteoclast: Making Headway to Osteoporosis Treatment
Current Drug Targets Subject Index To Volume 7
Current Drug Targets Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Current Pharmaceutical Design Macrophage Migration Inhibitory Factor and the Discovery of Tautomerase Inhibitors
Current Pharmaceutical Design Rheumatoid Nodulosis in a Patient with Lupus Erythematosus: Case Report and Review
Current Rheumatology Reviews Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy TNF, Cell Death and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents An in silico Workflow that Yields Experimentally Comparable Inhibitors for Human Dihydroorotate Dehydrogenase
Current Computer-Aided Drug Design ZnO-Nanorods as the Catalyst for the Synthesis of 1,3-Thiazole Derivatives via Multicomponent Reactions
Combinatorial Chemistry & High Throughput Screening Signal transduction in Acute Myeloid Leukemia – Implications for Novel Therapeutic Concepts.
Current Cancer Drug Targets Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design Dendrimers: General Aspects, Applications and Structural Exploitations as Prodrug/Drug-delivery Vehicles in Current Medicine
Mini-Reviews in Medicinal Chemistry Uric Acid and Diabetes: Is there a Link?
Current Pharmaceutical Design Pharmacogenomics of Methotrexate: Current Status and Future Outlook
Current Drug Metabolism Bhasma: Indian Perspective of Nanomedicinal Technology
Recent Patents on Nanomedicine Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design